Drug
Sgn Cd228a
Sgn Cd228a: highest development phase Phase 1, developed by Seagen. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Seagen
Trials
| Drug | Phase | Indication |
|---|---|---|
| SGN-CD228A NCT04042480 | Phase 1 | Cutaneous Melanoma |
Latest
No recent events.
Follow Sgn Cd228a on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.